Brokerages expect Retrophin, Inc. (NASDAQ:RTRX) to post sales of $40.50 million for the current quarter, according to Zacks. Two analysts have issued estimates for Retrophin’s earnings. The lowest sales estimate is $39.90 million and the highest is $41.10 million. Retrophin posted sales of $37.33 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.5%. The company is scheduled to issue its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Retrophin will report full-year sales of $40.50 million for the current financial year, with estimates ranging from $152.60 million to $153.90 million. For the next fiscal year, analysts expect that the firm will post sales of $175.45 million per share, with estimates ranging from $173.10 million to $177.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Retrophin.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The business had revenue of $40.34 million for the quarter, compared to analysts’ expectations of $40.51 million. During the same period in the prior year, the company earned ($0.09) EPS. The company’s revenue for the quarter was up 18.8% compared to the same quarter last year.
RTRX has been the topic of a number of recent analyst reports. BMO Capital Markets reissued a “buy” rating and set a $44.00 price target on shares of Retrophin in a research note on Friday, October 6th. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Finally, BidaskClub raised Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $36.00.
Retrophin (NASDAQ RTRX) opened at $21.13 on Wednesday. Retrophin has a 52 week low of $15.55 and a 52 week high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15.
Institutional investors and hedge funds have recently modified their holdings of the stock. Trexquant Investment LP purchased a new position in shares of Retrophin in the 3rd quarter worth $203,000. SG Americas Securities LLC raised its position in shares of Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 146 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Retrophin in the 3rd quarter worth $212,000. Legal & General Group Plc raised its position in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 355 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Retrophin in the 3rd quarter worth $249,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.